The global cancer diagnostics market is projected to expand steadily at a CAGR 7.1% value, during the forecast period 2022-2032. In the year 2022, the market size is projected to expand and gain a global market valuation of US$ 191 Billion. Considering this increasing growth and demand in the global market, the cancer diagnostics market is expected to reach US$ 379 Billion by 2032.
Technological advancements in various fields such as biopsy, imaging, biomarkers and endoscopy, rising prevalence of cancer, increase in government initiatives for creating awareness, rapidly increase in geriatric population, and growing government funding are key factors driving the growth of the cancer diagnostics market.
Timely detection of cancer requires suitable diagnostic tests to screen the immunosuppressed population which is at moderate risk of cancer, particularly for lung cancer, cervical cancer, breast cancer, prostate cancer, colon cancer and melanoma. Growing awareness of early signs and symptoms of cancer among physicians and other healthcare professionals as well as among the general population supplements the growth of cancer diagnostics.
Inclusion of cancer screening tests in National Cancer Screening Programs is another major factor expected to fuel the demand for cancer diagnostics. Introduction of regular mammography into national cancer programs by major developed countries where the incidence of breast cancer is high that is leading towards increasing adoption of cancer diagnostics in developed region.
For instance, the U.S. government has included the National Mammography Program in its national cancer screening programs. The government of Australia is taking initiative by conducting 3 cancer screening programs such as the National Cervical Screening Program, BreastScreen Australia and the National Bowel Cancer Screening Program. Similarly, most of the countries in Europe are continuously adopting HPV DNA screening for cervical cancer as a part of national cervical cancer programs.
Short-term Negative Impact Likely Due to COVID-19
The cancer diagnostics market is expected to experience short-term negative growth owing to a reduction in the cancer diagnosis procedures and adoption rate in developed and emerging countries. COVID-19 has impacted the landscape of cancer diagnostics. This has affected demand in various fronts, from prevention to screening and diagnosis, palliative care, treatment, and patient follow-up, to logistics and supplies of cancer diagnostic tests kits and other essential commodities.
Nonetheless after a period of muted growth, the market is poised to recover as economies return to normalcy. As per FMI, the rising incidence of lung cancer is attributable for over 19% of sales in the market.
Key Takeaways from Cancer Diagnostics Market Study
- The rising incidence of cancer will fuel the demand for cancer diagnostics, enabling the market register 8.5% CAGR between 2021 and 2022
- Increasing cases of cancer in the U.S. accounts for 84% of demand in North America
- Increasing healthcare spending will enable the U.K. market register over 5% y-o-y growth in 2021
- Favorable reimbursement policies will support growth in France and Germany
- Expansion of the healthcare sector will support growth in Japan and South Korea
“Advancements in cancer diagnostics and rising prevalence of cancer are expected to aid growth of cancer diagnostics. A majority of leading players in cancer diagnostic market are adopting strategic partnerships to sustain the increasing competitive pressure,” says the FMI Analyst
Get Sample PDF Brochure:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1090
Who is Winning?
Partnerships between cancer diagnostic assay kits developers, instrument manufacturers and technology licensers are often intended to increase the consumer base.
For instance, in March 2021, Illumina, Inc. signed a partnership agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits by using Illumina’s NextSeq 550Dx sequencing platform for cancer.
In June 2020, Thermo Fisher Scientific signed an agreement with Daiichi Sankyo to Co-launch a companion diagnostic for patients with non-small cell lung cancer for identifying Her2 gene mutations using the Oncomine Dx target test.
Cancer Diagnostics Market by Category
Test Type
- Tumour Biomarkers Tests
- PSA Tests
- CTC Tests
- AFP Tests
- CA Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Others
- Imaging
- Ultrasound
- Mammography
- MRI Scan
- PET Scan
- CT Scan
- SPECT & Others
- Biopsy
- Needle Biopsy
- Endoscopic Biopsy
- Bone Marrow Biopsy
- Others
- Liquid Biopsy
- Immunohistochemistry
- In Situ Hybridization
Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Blood Cancer
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
- Others
End-user
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
Ask for Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-1090
Table of Content
- Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
- Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Market Dynamics
2.4. Inclusions and Exclusions
- Market Background
3.1. Macro-Economic Factors
3.1.1. Global GDP Growth Outlook
3.1.2. Global Healthcare Expenditure Outlook
3.1.3. Growth of Healthcare Sector in Emerging Nations
3.2. Forecast Factors – Relevance & Impact
3.2.1. Global Increase in Healthcare Expenditure
3.2.2. Rising Prevalence of Cancer
3.2.3. Changing Regulatory Dynamics
3.2.4. Cost Impact
3.2.5. Regulatory Scenario
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunity Analysis
Get In Touch With Our Team For 30% Flat Discount: https://www.futuremarketinsights.com/ask-question/rep-gb-1090
ABOUT FUTURE MARKET INSIGHTS, INC.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Enquiries: sales@futuremarketinsights.com
